Chapter 81: Antifungal Agents

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about treating an infection, there's this expectation of, like, clinical precision.

Right, a really targeted approach.

Yeah, it's like a specialized demolition job.

Yeah.

So if a patient comes in with a bacterial infection,

you prescribe an antibiotic that targets the bacterial cell wall.

Exactly.

The bacteria explode and the human host's cells are left completely untouched.

Why?

Because human cells don't have cell walls.

Which is a very comforting thought for clinicians.

I mean, we desperately want our therapeutic targets to be visible, unique, and just entirely separate from human biology.

It makes the math of prescribing so much It really does.

But then you step into the world of mycosis, fungal infections, and suddenly that clean demolition job turns into a hostage situation.

Because the enemy looks an awful lot like the hostages.

Right.

The diagnostic and therapeutic landscape just becomes incredibly murky.

Fungi, unlike bacteria, are eukaryotes.

So they share an uncomfortable amount of cellular machinery with us.

And that shared machinery is what makes pharmacology in this area so perilous when the organism invading the body has a cellular structure that mimics the host's structure.

Designing a drug to kill the invader without harming the host requires some intense biochemical gymnastics.

Oh, absolutely.

It's a massive challenge.

Well, welcome to this deep dive.

If you are tuning in, you are likely an advanced practice nursing or physician assistant student, and you've joined us for a highly targeted last minute lecture tunering session.

We're glad you're here.

Our mission today is laser focused.

We are tackling chapter 81 of Lynn's pharmacotherapeutics for advanced practice nurses and physician assistants.

The third edition specifically.

Yes.

We are going to master antifungal agents, moving right through the text so you can connect the underlying pack of physiology directly to safe, rational drug selection and monitoring.

Because understanding the underlying mechanism, like knowing why a specific drug is chosen or why a black box warning actually exists at the cellular level.

That's the key to safe practice.

It really is.

Memorizing lists of side effects won't help you in a complex clinical scenario.

We need to look at the clinical reasoning behind the dothing charts and the safety alerts.

Okay, let's unpack this.

To understand how to fight fungal infections, we first have to understand the enemy and the battlefield.

Right.

So we are dealing with fungi, which broadly categorize into And they are absolutely omnipresent in our environment.

Everywhere.

And the source text notes something really startling right at the start, actually.

Climate change is promoting their growth globally.

Oh, wow.

Because fungi thrive in warmer temperatures.

Exactly.

Combine that environmental shift with frequent clinical misdiagnoses, and we are seeing these infections become increasingly common.

But they don't affect everyone equally, right?

No, not at all.

The high risk patient on this battlefield is almost always immunocompromised in some way.

So in clinical practice, you're primarily looking out for patients with HIV or AIDS, or patients taking immunosuppressant drugs like glucocorticoids for autoimmune diseases.

Yes, or patients who have developed a fungal superinfection after taking a long course of broad spectrum antibiotics.

Right, because the antibiotics wiped out their normal protective bacterial flora.

You've got it.

That leaves the door wide open for fungi.

Okay, so the infections themselves generally split into two main categories,

right?

Superficial and systemic.

Let's start superficial, which involves the skin, nails, and mucous membranes.

We have the dermatophytes, which cause the various tinea infections.

Commonly known as ringworm.

Right.

There's tinea pedis, which is athlete's foot.

That usually responds beautifully to topical therapies.

And there's tinea corpus on the body, and tinea crurus in the groin.

But then we have tinea capitis, which is on the scalp.

And topicals don't really work there.

They simply cannot penetrate deeply enough into the hair follicles.

So for the scalp, you're committing the patient to systemic oral therapy.

Yeah, the clinical guidelines outline six to eight weeks of a standard oral drug, like grizovolvin, or potentially two to four weeks of oral turbinifime.

Which tends to be more effective, but comes with its own systemic risks, which we'll get to.

Exactly.

Then we have candidiasis.

Vulvavaginal candidiasis is incredibly common.

I mean, the text notes, 75 % of women will experience it at least once.

It's easily curable, though, usually with one to three days of topical therapy, or a single 150 -milligram oral dose of fluconazole.

But as a clinician, you have to counsel the patient that choosing the convenience of the oral route carries more systemic side effects, right?

Like headaches and GI disturbance.

Right.

And of course, there's oral candidiasis or thrush.

You'll see this presenting as a thick white coating on the tongue and oral mucosa.

Which often requires a topical swish and swallow routine or oral therapy if the host is immunocompromised.

But the real clinical headache in the superficial category is onychomycosis.

The nail infections.

Yes.

It severely thickens, discolors, and deforms the nail plate.

You know, treating onychomycosis feels like trying to weed a garden where the roots are hidden entirely under a thick concrete slab.

That is a perfect analogy.

You can't just spray the surface of the nail and expect a cure.

It takes months of systemic effort, usually three to six months of daily oral medication.

And even with that prolonged therapy, you still might only achieve a 50 % success rate.

And here is the kicker.

It's largely a cosmetic concern.

Right.

Now, if superficial infections are the weeds in the garden, systemic mucoses are a fire in the house.

These are much more serious, notoriously difficult to diagnose early, and potentially fatal.

They subdivide into opportunistic infections like candidiasis and aspergillosis, which strike the debilitated and immunocompromised.

And non -opportunistic infections like histoplasmosis, which you can inhale into the lungs and infect perfectly healthy hosts.

Exactly.

So we have an enemy that can cause everything from a slightly itchy toe to a lethal systemic collapse.

And because fungi have both a cell membrane and a cell wall, we need specific targeted weapons.

Let's look at the absolute heaviest hitter of them all.

The polyin antibiotics.

Specifically, amphotericin B.

This is the pharmacological sledgehammer.

The mechanism of action is brutal, but effective.

Amphotericin B binds to a specific sterol found in the fungal cell membrane called ergosterol.

Okay.

So by binding to it, the drug physically alters the membrane structure, increasing its permeability.

It essentially forces pores or holes to open in the fungal cell membrane.

Which causes a massive leakage of intracellular cations, primarily potassium, right?

Right.

And without that internal potassium, the cell loses viability and dies.

It is a broad spectrum killer, making it the drug of choice for most life -threatening systemic mycosis.

But the pharmacokinetics make it incredibly difficult to administer.

It's poorly absorbed from the GI tract.

For systemic infections, you absolutely must give it intravenously.

It binds extensively to tissues throughout the body, but strangely it doesn't easily penetrate the cerebrospinal fluid.

And then we have to talk about the toxicity.

The black box warning on amphotericin B is severe.

The toxicity cannot be overstated here.

The black box warning dictates it should only be used for progressive, potentially fatal infections.

So you do not use this drug for a stubborn case of thrush?

Never.

When you hang an IV bag of amphotericin B, you are practically guaranteed to see violent infusion reactions and some degree of renal damage in your patient.

Let's visualize those infusion reactions for a second.

Patients get hit with high fevers, shaking chills, rigors, and severe nausea.

And it usually happens one to three hours post -infusion.

Why does it happen so predictably?

Because the drug triggers the body's monocytes and macrophages to release massive amounts of pro -inflammatory cytokines.

It's like a localized cytokine storm.

Exactly.

You have to pre -treat these patients with diphenhydramine and acetaminophen just to make it tolerable.

But the text specifically warns against the routine use of hydrocortisone for these chills.

Why hold back on the steroids?

You have to consider the underlying pathophysiology of the patient.

Glucocorticoids like hydrocortisone actively suppress immune function.

Oh, right.

In a patient who is already fighting a life -threatening systemic fungal infection, suppressing their immune system further just to manage the chills is an incredibly dangerous trade -off.

You might stop the rigors, but you give the fungus an unprotected host.

That makes total sense.

And the nut for toxicity is another massive issue.

The text points out that kidney damage happens in almost all patients receiving this drug.

Almost all?

Wow.

So how do you mitigate that?

Clinicians are advised to infuse a full liter of saline on the days amphotericin is administered to help flush the kidneys.

And you absolutely must monitor kidney function every three to four days.

If their plasma carotidin rises above 3 .5 milligrams per deciliter, you have to reduce the dosage immediately.

On top of all that, it causes bone marrow suppression, so you're constantly monitoring hematocrit levels for anemia.

And obviously, you have to avoid prescribing any other nephrotoxic drugs simultaneously, like NSAIs or aminoglycosides.

Right.

Now, it's worth briefly noting two other polyenes in this class that don't have the same systemic dangers because of how they are administered.

Natamycin and nystatin, right?

Yes.

Natamycin is an ophthalmic preparation specifically for fungal eye infections, and nystatin is minimally absorbed from the GI tract.

Which makes nystatin fantastic as a topical powder or cream or as an oral swish and swallow liquid for thrush.

Exactly.

It stays exactly where you put it, kills the fungus locally and passes through the body without causing that horrific systemic toxicity.

Okay.

Let me push back here on the main systemic drug.

If Amphotericin B is so highly toxic that it practically guarantees kidney damage, causes massive cytokine storms, and drops the patient's red blood cell count,

why on earth is it still considered the gold standard drug of choice for systemic infections?

That's a great question.

Before Amphotericin B became widely available, systemic fungal infections were almost universally a death sentence.

The toxicity is a necessary calculated trade -off for survival.

Remember our earlier discussion about the host cells looking uncomfortably like the fungal cells?

Right.

Fungi use ergosterol for their membranes.

Humans use cholesterol.

Exactly.

The toxicity occurs because Amphotericin B doesn't just bind to fungal ergosterol.

It also binds, albeit slightly less strongly, to the cholesterol in human mammalian cell membranes.

Ah.

So it pokes holes in the fungus, but it also pokes smaller holes in us.

That cross -reactivity is the price of admission for curing a fatal infection.

Wow.

Okay.

So Amphotericin B is basically a chemical grenade.

We obviously can't use it for a simple case of athlete's foot or a persistent nail infection.

Definitely not.

We need a weapon that is highly selective, something that targets the fungus without touching human cells.

How do we achieve that?

We shift our focus from destroying the existing membrane to stopping the fungus from building the membrane in the first place.

Okay.

This is the mechanism of the allylamines, like Turbinifine.

They are highly selective.

They inhibit a specific fungal enzyme called squalene epoxidase, right?

Yes, which completely halts the synthesis of ergosterol.

Because it targets an enzyme unique to the fungal building process, there's significantly less collateral damage to human cholesterol.

Turbinifine is a fascinating drug.

You'll see the topical formulations sold over the counter for those superficial tiny infections, the itchy feet and rashes.

But the oral tablets are prescribed for onyotomycosis, the stubborn nail infections.

And the pharmacokinetics for oral Turbinifine are just wild.

It has a terminal half -life of 8 to 16 days.

It is highly lipophilic, meaning it loves fat, and it deposits deeply into the skin, hair, and nail beds, lingering there for a very long time.

While the topical side effects are mostly localized irritation,

prescribing oral Turbinifine is a different story entirely, isn't it?

Oh, absolutely.

The most common side effect is a simple headache, but it carries serious life -threatening risks.

Like severe hepatotoxicity and devastating skin reactions like Stevens -Johnson syndrome and D -DRESS.

Right, drug reaction with eosinophilia and systemic symptoms.

Furthermore, it inhibits the specific liver enzymes that metabolize other common drugs.

Meaning it can raise the levels of medications the patient is already taking, like antidepressants or beta blockers, to toxic levels.

Exactly.

As a CYP2D6 inhibitor, you have to be so careful.

So what does this all mean?

Think about the clinical reasoning here.

Imagine you have a patient sitting in front of you with a purely cosmetic nail infection.

Is prescribing a systemic drug with a 16 -day half -life, significant drug interactions, and serious, albeit rare,

risks of liver toxicity and severe skin sloughing syndromes truly worth it for a coin -flip chance at a prettier toenail?

That's the kind of person -centered clinical judgment you have to develop.

You aren't just treating the nail.

You have to evaluate the whole patient.

The alamines are excellent tools, but they require highly careful patient selection and informed consent regarding those risks.

Agreed.

So we've got topicals and selective systemic drugs for superficial issues, and a highly toxic sledgehammer for life -threatening systemic issues.

What's the middle ground when we need a safer, broad -spectrum alternative to Amphotericin B for true systemic infections?

We turn to the Azoles.

They are broad -spectrum, they have much lower toxicity than Amphob, and crucially, they are available orally.

Meaning the patient doesn't need to be hooked up to an IV.

Right.

But there is a massive physiological trade -off.

Taking an oral Azole is like hosting a very demanding house guest.

It requires a specific environment to even settle in, and once it does, it completely takes over your household routine.

In this case, it takes over your liver's metabolic pathways.

The prototype drug here is Itraconazole.

Like the alamines, it inhibits the synthesis of ergosterol, starving the fungal membrane.

And clinicians use it for severe systemic infections like aspergillosis and histoplasmosis.

But let's explore that demanding house guest metaphor, starting with how the drug actually gets absorbed.

The absorption quirk is fascinating.

If you prescribe the capsule form of Itraconazole, it absolutely requires a highly acidic environment in the stomach to dissolve and absorb.

Its absorption is actually enhanced if the patient swallows it with a glass of cola.

Wait, really?

A glass of cola?

Yeah.

But if your patient is taking antacids, H2 blockers, or proton pump inhibitors for heartburn, the stomach acid drops, and the antifungal absorption is essentially ruined.

The drug just passes right through.

Assuming you manage to get the drug absorbed, you then have to navigate the black box warning for Itraconazole.

While it is generally much better tolerated than Amphotericin B, it has negative inotropic actions.

Right.

In plain terms, it decreases the force of the heart muscle's contraction.

It can cause or severely worsen heart failure.

The warning explicitly states you must not use it for superficial infections in patients with ventricular dysfunction.

Pushing a weakened heart to pump with even less force can be catastrophic.

And like many systemically metabolized antifungals, it carries a risk of rare but fatal liver failure.

Let's talk about the metabolic traffic jam it causes in the liver.

Itraconazole monopolizes the specific CYP3A4 liver enzymes that process dozens of other common medications.

So if your patient is taking a blood thinner or an immunosuppressant or a heart medication, the liver is suddenly too busy dealing with the antifungal to process those other drugs.

The other medications build up in the bloodstream, and suddenly you have a massive bleeding risk or toxic immunosuppression or fatal ventricular dysrhythmias.

You have to hyper monitor concurrent use of drugs like cyclosporine, digoxin, and warfarin.

We should briefly highlight two other notable azoles because their metabolic footprints are equally significant.

Fluconazole strongly inhibits a different set of liver enzymes, CYP2C19, and requires highly careful dosage adjustments in patients with renal impairment.

And ketoconazole carries its own black box warning for hepatotoxicity and heart rhythm prolongation.

But it has a unique troubling adverse effect, right?

It actively decreases the body's synthesis of both testosterone and cortisol.

Yes, this can cause temporary infertility, gynecomastia, and severe adrenal suppression.

Okay, let's reset the battlefield.

All of these drugs, amphotericin, turbinofine, etraconazole, they all go after the cell membrane.

But fungi don't just have a membrane, they also have a rigid cell wall surrounding that membrane.

If we want a different approach, we turn to the drugs that smash the wall, the echinocandins.

The prototype drug in this class is caspofungin.

The mechanism of action shifts completely away from ergosterol.

Echinocandins inhibit the synthesis of beta -1 -volatee -glucan, which is a vital structural component of the fungal cell wall.

Without this glucan, the wall loses its structural integrity and the cell ruptures.

Because human cells don't synthesize glucan, this is a highly targeted attack.

And the major pharmacological benefit.

They do not cause that massive liver enzyme traffic jam we just discussed with the azoles.

Right, they don't inhibit or induce CYP450 enzymes.

That sounds like an incredible relief.

Does the lack of liver enzyme interaction make echinocandins the ideal choice for complex patients who are taking 10 different medications?

They are incredibly useful, but they have significant limitations.

First, they have a very narrow spectrum of activity, primarily approved just for severe aspergillus and candida infections.

And second, they are strictly available via IV, so they are limited to clinical settings.

Interestingly, they are cleared from the plasma by slowly distributing into the tissues, rather than requiring immediate liver metabolism or kidney excretion.

And the adverse effects aren't zero.

When infusing caspofungin, about 30 % of patients experience histamine -mediated infusion reactions.

We're talking sudden rashes, facial flushing, and a dangerous drop in blood pressure.

And even though they don't block the main metabolic pathways in the liver, they still have drug interactions.

Combining caspofungin with the immunosuppressant cyclosporine increases the risk of liver injury.

It can also unexpectedly decrease the blood levels of another immunosuppressant tecrullamus.

Meaning the clinician has to monitor those drug trough levels obsessively to prevent organ rejection.

Exactly.

Prescribing any of these drugs isn't just about matching the mechanism to the fungus.

You have to match the drug to the specific life stage of the patient sitting in front of you.

The lifespan considerations detailed in the text are a literal minefield.

Age and reproductive status change everything.

For infants, nystatin is generally safe for treating oral thrush.

But clinicians must carefully read the labels to avoid copicle formulations containing propylene glycol, which can be highly toxic to neonates.

And pregnancy?

Well, that requires extreme caution.

The text is incredibly strict here.

The absorbable azoles are broadly not recommended in the first trimester.

Lucanazole is directly associated with spontaneous abortions and severe fetal harm.

Systemic turbinofine, itracanazole, and caspofungin are all suspected of causing fetal harm and are generally not recommended.

Basically, if the drug goes systemic,

you are walking on very thin ice during pregnancy and must weigh the threat to the mother's life against the near certainty of fetal toxicity.

Looking at older adults, the clinical risks shift toward absorption and metabolism.

Older adults have a significantly higher risk of achlorhydria.

Which is a reduction in stomach acid production.

Right.

Remember how atracanazole required a highly acidic environment, like a glass of cola, to absorb?

Yes.

So low stomach acid in older adults means highly unpredictable drug absorption.

Furthermore, older adults are statistically much more likely to be experiencing polypharmacy, making those azole -induced liver enzyme traffic jams, especially with blood thinners like warfarin, an everyday clinical hazard.

We have three final highly specialized classes to cover that round out the antifungal arsenal.

First, the Pyrimidine analog.

Flucytosine.

This one takes a completely different path.

Flucytosine is taken up by the fungal cell and converts into a compound that disrupts fungal RNA and DNA synthesis.

It stops the fungus from replicating its genetic code.

It has a narrow spectrum and is almost always combined with amphotericin B to prevent the fungus from developing resistance and to enhance overall lethality.

But wait, here is the massive clinical paradox.

Flucytosine is cleared almost entirely by the kidneys.

And the text features a black box warning demanding extreme caution in patients with renal impairment.

Because if the kidneys can't clear it, it builds up and becomes lethally toxic to the bone marrow.

Right.

But its partner drug, amphotericin B, is famous for causing severe renal impairment.

I know.

You're telling me we take a drug cleared by the kidneys and give it simultaneously with a drug famous for destroying the kidneys.

It is a profound high -wire balancing act.

You are intentionally giving a nephrotoxic drug alongside a drug that becomes fatal if the kidneys fail.

Navigating this combination requires microscopic clinical attention.

You are monitoring intake and output hourly, checking daily creatinine levels, and running weekly leukocyte and platelet counts to prevent fatal agranulocytosis.

It requires absolute clinical vigilance.

Here's where it gets really interesting.

Let's look at the mitotic inhibitor, Gruesophil fulvin.

This is an oral drug used specifically for dermatophytes, those superficial skin and nail infections.

Its absorption is uniquely enhanced if the patient takes it with a fatty meal.

But the mechanism is brilliant.

It doesn't actually assassinate the fungus directly.

No, it is fungistatic, not fungicidal.

It enters the body and halts fungal mitosis.

It stops the fungal cells from dividing.

But the brilliant part is where the drug hides.

It deposits itself exclusively into the newly formed keratin precursor cells in the skin, hair, and nails.

It effectively builds a fortress.

As the new, healthy nail or skin tissue grows, it is completely saturated with the drug, making it totally resistant to fungal invasion.

The drug just maintains the fortress and waits out the siege until the old, infected skin or nail naturally grows out and flakes off.

That's why treating a toenail with Gruesophil fulvin can take a year or more.

You're literally waiting for an entirely new toenail to grow from scratch.

Finally, we should mention the newest class, approved in 2021, the tritopinoids.

The prototype drug is ibrexafungerp.

Similar to the akamakandins, it inhibits glucan synthase to disrupt the cell wall, but the major breakthrough is that it's an oral tablet.

Used specifically to treat vulvovaginal candidiasis.

However, clinicians must be hypervigilant regarding its black box warning.

It is absolutely contraindicated in pregnancy due to confirmed fetal harm.

You must empirically verify a non -pregnant status before prescribing it.

And for minor topical issues where we don't want to risk any of this systemic chaos, we still have reliable over -the -counter agents.

Tolnoftate and undiscellenic acid are great for athlete's foot.

And sicklepirox comes as a topical nail lacquer, with zero systemic toxicity for mild nail infections.

When we pull all of these complex mechanisms, black box warnings and drug interactions together, a very clear narrative emerges for the prescribing clinician.

Understanding the exact pathophysiology of the fungus supports your therapeutic goals, and those goals dictate rational,

safe drug selection.

Exactly.

Well, mission accomplished.

If you are prepping for your exams or your next clinical rotation, you have successfully bridged the gap between understanding basic fungal structures and making safe, rational prescribing decisions across seven incredibly complex drug classes.

A huge warm thank you to the student from the Last Minute Lecture team who requested this session.

You are going to crush your exams and make an incredible, deeply informed clinician.

I want to leave everyone with a final thought to ponder, based on a single line from the very first page of Chapter 81.

We noted earlier that climate change is actively expanding the geographical footprint and growth rates of fungi worldwide.

So if these deep systemic mycosis transition from being relatively rare, opportunistic infections to common everyday occurrences in our clinics, how will our healthcare system handle it?

How will we safely manage the intense toxicity, the cardiac and hepatic black box warnings, and the multi -month 5E treatments required by our current antifungal arsenal on a massive scale?

It's a sobering thought,

because if that biological hostage situation becomes the new normal, we are going to need a lot more than sledgehammers to get out of it safely.